Neurophth Therapeutics

Executive Summary

Neurophth Therapeutics is a clinical-stage biotech company and China's leader in ocular gene therapy, developing AAV-based treatments for inherited retinal diseases. Its lead candidate, NFS-01 (NR082), is in Phase 3 trials for Leber's hereditary optic neuropathy (LHON), a rare mitochondrial disorder causing irreversible vision loss. With over $950 million raised, the company has built a robust pipeline targeting dominant optic atrophy, optic nerve injury, and vascular retinopathies. Neurophth's differentiated approach leverages proprietary AAV vectors and deep expertise in ophthalmic gene therapy, positioning it to address significant unmet medical needs in ophthalmology. The company is private, headquartered in Wuhan, China, and employs 200–500 staff. Neurophth's near-term value hinges on the successful completion of Phase 3 trials for NR082, which could become the first approved gene therapy for LHON globally. The company is also advancing earlier-stage programs, including NFS-02 for dominant optic atrophy and preclinical candidates for optic nerve injury. Market opportunity is substantial given the lack of effective treatments for these blinding diseases. Key risks include regulatory hurdles in China and the U.S., clinical trial execution, and manufacturing scalability for AAV therapies. Nonetheless, Neurophth's leadership in Chinese ocular gene therapy and strong financial runway support its potential to become a major player in the ophthalmic gene therapy space.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 topline data for NFS-01 (NR082) in LHON65% success
• H1 2027Potential NDA submission in China for NFS-0170% success
• H2 2026Phase 1/2 data for NFS-02 in dominant optic atrophy50% success